Skip to main content
. 2022 Jul 9;10(7):1654. doi: 10.3390/biomedicines10071654

Figure 7.

Figure 7

Impacts of quercetin-loaded nanoparticles (QT-NPs) therapy on mRNA expression of tight junction-related genes mucin-2 (MUC-2) (a), junction adhesion molecule (JAM) (b), occludin (c), nuclear factor erythroid 2-related factor 2 (NRF2)-Kelch-like erythroid cell-derived protein (d), heme oxygenase-1 (Hmox1, HO-1) (e), gene encoding the CD4 membrane glycoprotein of T lymphocytes (f), gene encoding the CD8 membrane glycoprotein of T lymphocytes (g), toll-like receptor-4 (TLR-4) (h) 14 days post DSS induction. Mean values with different letters in the same row differ significantly at p < 0.05, SE: standard error. a–e Means of the rows with different letters were significantly different among groups (p < 0.05). Control: healthy non-colitic group (rats orally gavaged with PBS); colitic groups: DSS (rats orally gavaged with dextran sodium sulphate), DSS + QT-NPsI (rats orally gavaged with DSS and quercetin-loaded nanoparticles (QT-NPs at the level 10 mg/kg body weight for 14 days)), DSS + QT-NPsII (rats orally gavaged with DSS and quercetin-loaded nanoparticles (QT-NPs at the level 15 mg/kg body weight for 14 days)), and DSS + QT-NPsIII (rats orally gavaged with DSS and quercetin-loaded nanoparticles (QT-NPs at the level 20 mg/kg body weight for 14 days)). All groups orally gavaged by 3% DSS.